Cat NO.:	EL0185Hu
Product:	Sunlong Medical™ Human IL-12/IL-23 p40 ELISA Kit
Storage	4℃ (unopened) for two years
Shipping Condition	4℃
Sample Type:	Serum | plasma | cell culture supernatant and other biological samples
Spike Recovery Range:	88% - 115%
Mean Spike Recovery:	1.05
CV of Intra plate:	4.9 % - 6.2 %
CV of Inter plate:	3.7 % - 5.7 %
NCBI_Gene:	Inquiry
UniProtKB:	Inquiry

 

PLATFORM	ELISA
PLATE	Detachable 96-well plate
SIZE	96T/48T
STORAGE	If the reagent kit is unopened, it should be stored at 4℃. However, if it has been opened, the standard solution should be stored at -20℃, while the other components should be stored at 4℃.
DELIVERY	4℃ blue ice transportation
COMPONENTS	96-well polystyrene enzyme-linked immunosorbent assay (ELISA) plate coated with anti-IL-12/IL-23 monoclonal antibody Human IL-12/IL-23 freeze-dried standard IL-12/IL-23 detect Antibody Standard Diluent Assay Buffer(10×) Substrate TMB Stop Solution Washing Buffer(20×) Sealing Film
ASSAY PRINCIPLE	This kit utilizes the double antibody sandwich enzyme-linked immunosorbent assay (ELISA) detection technique.Specific anti-human IL-12/IL-23 p40 antibodies are precoated on a high-affinity ELISA plate. Standard samples, test samples, and biotinylated detection antibodies are added to the wells of the ELISA plate. After incubation, IL-12/IL-23 p40 present in the samples binds to the solid-phase antibodies and the detection antibodies. After washing to remove unbound substances, streptavidin-HRP labeled with horseradish peroxidase is added. After washing, a colorimetric substrate, TMB, is added and the plate is incubated in the dark for color development. The intensity of the color reaction is directly proportional to the concentration of IL-12/IL-23 p40 in the samples.A stop solution is added to terminate the reaction, and the absorbance value is measured at a wavelength of 450 nm (with a reference wavelength range of 570-630 nm).

 

1. XFab-α4-1BB/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models

CANCER IMMUNOLOGY IMMUNOTHERAPY 2023-10-21

Cartpieces

• 
• 1

  1Delete

• 
• 6

  6Delete

• 
• E

  EDelete

• 
• S

  SDelete

• 
• +

  +Delete

• 
• 2

  2Delete

• 
• 2

  2Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 5

  5Delete

• 
• $

  $Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• S

  SDelete

• 
• I

  IDelete

• 
• <

  <Delete

• 
• i

  iDelete

• 
• i

  iDelete

• Delete

• 
• 1

  1Delete

• Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• Delete

• 
• 2

  2Delete

• 
• 1

  1Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 1

  1Delete

• 
• 1

  1Delete

• Delete

• 
• -

  -Delete

• 
• -

  -Delete

• 
• 0

  0Delete

• Delete

• Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• 
• f

  fDelete

• Delete

• Delete

• 
• 0

  0Delete

• 
• 0

  0Delete

• Delete

• 
• <

  <Delete

• Delete

• Delete

• Delete

• Delete

• Delete

• 
• S

  SDelete

• Delete

• Delete

• 
• 5

  5Delete

• 
• $

  $Delete

• Delete

• 
• 0

  0Delete

• Delete

• Delete

• Delete

• 
• b

  bDelete

• 
• S

  SDelete

• 
• 5

  5Delete

• 
• S

  SDelete

Totalgoods,subtotals:￥Checkout